significance level of 0.05 was used for these analyses. RESULTS: Overall 7,261 enrollees were included in the analysis. Out of these, 187 (2.6%) had HF at baseline and 1,075 (14.8%) experienced HF for the first time. Mean LOS was 4.29 (Ϯ7.5) days but increased significantly to 8.8 (Ϯ17.6) days in case of new onset HF (␤ ϭ 5.2Ϯ0.2, pϽ0.001) and to 9.7 (Ϯ10.5) days if pre-existing HF was included as a major comorbidity (␤ ϭ 6.0Ϯ0.7, pϽ0.001) during index hospitalization. Hospitalization costs (log-transformed) were associated with recording of new onset HF (␤ ϭ 0.4Ϯ0.02, pϽ0.001) but not with reporting of pre-existing HF (␤ ϭ 0.1Ϯ0.1, pϽ0.1451) as a comorbid condition during index hospitalization. CONCLUSIONS: New onset of HF, recorded as a major comorbid condition, in STEMI patients undergoing PCI exhibited significant independent association with resource utilization including increased length of stay and greater costs.
OBJECTIVES:
To evaluate persistence and compliance of fixed dose combinations in comparison to unfixed dose combinations of angiotensin receptor blockers (ARBs) in patients with hypertension in Germany. METHODS: This retrospective study analyzed prescription data collected by general practitioners, using a longitudinal database, the German IMS Disease Analyzer (DA). The DA database was searched for patients with hypertension (ICD-10 code I10) who were initiated on double or triple combinations of ARBs with hydrochlorothiazide (HCT) and/or amlodipine (AML) in the period 09/2008-08/2009 with a follow-up of at least 12 months. Persistence was defined as proportion of patients who remained on their initially prescribed therapy at 1 year. The difference between mean persistence values (days) were calculated by using multiple regression analyses adjusted by age, gender, region, insurance and co-morbidity. Compliance was measured indirectly based on the medication possession ratio calculated as number of days supplied within the refill interval in relation to the number of days in the refill interval. RESULTS: Overall, 17,310 patients were eligible for analysis: 35.7% on a fixed double ARB combination, 33.0% on an unfixed double ARB combination, 25.9% on a semifixed triple ARB combination, and 5.4% on an unfixed triple ARB combination. Twelve months after first prescription persistence on unfixed versus semi-fixed ARB/HCTϩAML triple combination was 32.7% and 46.7 % respectively, unfixed versus semi-fixed ARB/AMLϩHCT triple combination was 41.5% and 49.0% respectively, unfixed versus fixed ARB/HCT double combination 23,8% and 41.1% respectively, unfixed versus fixed ARB/AML double combination 27.5% and 44.4% respectively. Mean days of persistence was higher in patients receiving fixed combinations (225.7-242.9) compared to unfixed combinations (163.6-228.0). Mean compliance value with fixed combinations ranged between 72.0%-79.0%, with unfixed combinations between 71.5-76.2%. CONCLUSIONS: These real-life data confirms previous study results, that fixed combinations improve persistence in patients compared to unfixed combinations because of reduced pill burden.
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MEDICATION ADHERENCE, PERSISTENCE, AND HEALTH CARE COSTS FOR PATIENTS INITIATING STATIN THERAPY IN A MANAGED CARE POPULATION
Zhao Z 1 , Peng X 1 , Bae JP 1 , Dungey J 1 , Faries DE 1 , Sponseller CA 2 , Wetmore S 1 , Yu CY 1 , LeNarz LA 1 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Kowa Pharmaceuticals America, Inc., Montgomery, AL, USA OBJECTIVES: Compare statin adherence, persistence, and health care costs among patients in whom atorvastatin (AS), simvastatin (SS), rosuvastatin (RS), or pravastatin (PS) was newly prescribed. METHODS: Study patients Ն18 years were identified between October 1, 2006-September 30, 2007, with a minimum 12-month preand 24-month post-index health plan eligibility from a managed care database. A 6-month washout period free of any statin use was applied to identify patients in whom statin therapy was newly prescribed. The index date was defined as the date of the first statin prescription and four cohorts were created based on index statins: AS, SS, RS, and PS. These cohorts were matched according to propensity scores based on patient clinical and demographic characteristics. Outcomes were compared among matched cohorts during the 2-year post-index period, including adherence to any statin (medication possession ratioՆ0.8), time to any statin discontinuation, and health care costs. RESULTS: After matching, 6185 patients were obtained in each cohort and the baseline characteristics were balanced among cohorts. Half of the patients were adherent to their statin therapy at 12 months (52.2% for SS, 47.3% for AS, 48.6% for RS, and 49.7% for PS, PϽ0.01), with further decline at 24 months (43.1% for SS, 38.0% for AS, 39.2% for RS, and 38.5% for PS, PϽ0.01). Median time to any statin discontinuation within 24 months were less than 1 year for all cohorts (SS: 308 days; AS: 250 days; RS: 266 days; PS: 301 days, PϽ0.01). The cohorts had slightly different 2-year health care costs (SS: $15,417; AS: $16,826; RS: $15,874; PS: $15,481, PϽ0.01) with the most difference attributable to the lower drug costs (SS: $4460; AS: $5485; RS: $5424; PS: $4586, PϽ0.01). CONCLUSIONS: Patients had low adherence and persistence rates to statin therapy. Patients initiating different statins had varying adherence and persistence profiles, including 2-year health care costs.
PCV61 THE IMPACT OF THE MEDICARE DOUGHNUT HOLE ON MEDICATION USE BEHAVIORS AND HEALTH CARE RESOURCE UTILIZATION AMONG BENEFICIARIES TAKING STATIN MEDICATION
Joshi N, Banahan BFI, University of Mississippi, University, MS, USA OBJECTIVES: The objective was to determine the impact of Medicare part D doughnut hole or the 'coverage gap' on medication compliance behavior and healthcare resource utilization among Medicare beneficiaries taking statin medications.
METHODS:
This was a retrospective cohort study using a 2007 5% National sample of Medicare beneficiaries. Beneficiaries enrolled in the Part D program with at least 1 prescription claim for statin were included in the study. Patients were classified as continuers, switchers and discontinuers of statin medications after reaching the coverage gap. The primary outcomes of interest were average number of emergency room (ER) visits, hospitalizations, out of pocket (OoP) costs and number of prescriptions pre and post coverage gap. RESULTS: 131237 patients met the inclusion criteria. All patients in the study sample were diagnosed with hyperlipidemia, and 8,251 patients were prescribed with statins as a primary prevention treatment. Of the beneficiaries taking statins, 65.8% were female; 80.71% white; 10.91% black and the mean age was 71.9 (Ϯ12.0) years. Overall, 24.3% of statin users reached the coverage gap in 2007, with 10.2% reaching the gap by March, 42.0% by June, and 74.4% by September. Within 90 days after reaching the gap, 74.2% of statin users continued using their statin medication, 1.0% switched to a different statin medication, and 24.8% discontinued use of statins. After reaching the coverage gap, the average number of ER visits/month increased from 0.24 to 0.25 and the average OoP costs/month increased from $58.51 to $104.03. CONCLUSIONS: The results suggest an overall negative impact of the Medicare part D coverage gap on enrollee health, adherence to statin medications, number of hospitalizations, emergency department visits and out of pocket expenses incurred by beneficiaries. The disruption of the coverage gap on the quality of care is demonstrated by the large percentage of statin users discontinuing therapy.
PCV62 PERSISTENCE AND COMPLIANCE IN HYPERTENSION TREATMENT WITH OLMESARTAN MEDOXOMIL -ANALYSIS OF REAL-LIFE PRESCRIPTION DATA
Sandberg A 1 , Kostev K 2 , Ehlken B 3 , Holz B 2 , Oberdiek A 1 1 Daiichi Sankyo Europe GmbH, Munich, Germany, 2 IMS Health GmbH & Co., Frankfurt, Germany, 3 IMS Health GmbH & Co., Munich, Germany OBJECTIVES: To evaluate treatment compliance and persistence in patients receiving fixed combinations compared to patients receiving unfixed combinations with olmesartan medoxomil for hypertension treatment in Germany. METHODS: This retrospective study analyzed prescription data collected by general practitioners, using a longitudinal database, the German IMS Disease Analyzer (DA). The DA database was searched for patients with hypertension (ICD-10 code I10) who were initiated on double or triple combinations of olmesartan medoxomil with hydrochlorothiazide and/or amlodipine in the period 09/2008-08/2009 with a follow-up of at least 12 months. Persistence was defined as proportion of patients who remained on their initially prescribed therapy at 1 year. The difference between mean persistence values (days) were calculated by using multiple regression analyses adjusted by age, gender, region, insurance and co-morbidity. Compliance was measured indirectly based on the medication possession ratio calculated as number of days supplied within the refill interval in relation to the number of days in the refill interval. RESULTS: In total, 7,360 patients were eligible for analysis, 58.0% were treated with a fixed or semi-fixed combination of olmesartan and 42.0% with a dual or triple unfixed combination of olmesartan. After 12 months following the first prescription, fixed or semi-fixed combinations had a higher rate of persistence (43.4%-50.2%) compared to dual or triple unfixed combinations (25.0%-35.8%). Mean duration of persistence was higher in patients receiving dual or triple fixed or semi-fixed combinations (222.5-242.7 days) compared to patients receiving unfixed combinations (183.6-205.0 days). Mean compliance value with olmesartan in all combinations ranged between 70.0% Ϫ80.0%. CONCLUSIONS: Overall, persistence is increased in patients receiving fixed combinations of olmesartan in comparison to free combinations. These real-life data confirms previous study results, that persistence of fixed combinations in comparison to unfixed combinations is improved because of reduced pill burden.
PCV63 THE IMPACT OF CARDIOVASCULAR DISEASE HOSPITALIZATIONS ON CHANGES IN PATIENT ADHERENCE TO ANTIHYPERTENISVE DRUGS IN A MEDICAID POPULATION
Yan X, Shaya FT University of Maryland School of Pharmacy, Baltimore, MD, USA OBJECTIVES: The impact of health behaviors (e.g., medication adherence) on outcomes (e.g., hospitalizations) has been widely explored in literature, but few studies have evaluated the reverse association. We investigated the impact of cardiovascular disease (CVD) hospitalizations on changes in adherence to antihypertensive (AH) drugs. METHODS: Maryland Medicaid claims data from January 2001 to June 2006 were analyzed. The index date for patients with a CVD hospitalization was the admission date of the first observed CVD-related hospitalization. Matched controls had the same index date as index patients. Proportion of days covered (PDC) was used to measure medication adherence (adherence: PDCՆ80%). Patients with and without a CVD hospitalization were matched 1:1, on the first pharmacy claim (Ϯ6 month) of any AH drugs recorded in the database, age (Ϯ5 years), gender, race, number of drugs taken in the 6-month pre-index period (Ϯ1 drug), and adherence rate to AH drugs in the 6-month pre-index period (Ϯ5% A43 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4
